RxDoctor Payments Data

Abigail Moeller, PA

Physician Assistant · Oklahoma City, OKNPI 1376783480

Payments from drug & device makers

$2,137in general payments, 2019–2025

Across 57 payments — averaging $37.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$715
  • Urogen Pharma, Inc.$328
  • Pfizer$204
  • Bayer$152
  • Boston Scientific$133
  • Foundation Medicine, Inc.$117
  • plus $488 from 10 others

What the payments were for

  • Food & beverage$1,95091%
  • Education$1879%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,137 in reported general payments places this provider in the 80th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$18,512
Medicare patients
177
Services billed
288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide89$1,070,280
ErleadaApalutamide13$186,345
OrgovyxRelugolix36$94,114
MyrbetriqMirabegron19$18,079
Abiraterone Acetate22$8,541
Tamsulosin Hcl144$3,723
Trimethoprim16$1,435
Trospium Chloride22$1,236
Dutasteride38$1,162
Finasteride41$858
Tolterodine Tartrate13$804
Alfuzosin Hcl ErAlfuzosin Hcl27$605
Solifenacin Succinate20$429
Imipramine Hcl22$318
Bicalutamide11$179

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$55$1,088,359108 claims
Johnson & JohnsonErleada$715$186,34513 claims
Sumitomo Pharma America, Inc.Orgovyx$27$94,11436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Oklahoma City

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →